MedPath

Evaluating Cinnamon Effects on Clinical, Serologic and Sonographic Characteristics of Non-Alcoholic Fatty Liver Disease patients

Phase 1
Conditions
on-Alcoholic Fatty Liver Disease.
Fatty (change of) liver, not elsewhere classified
Registration Number
IRCT2015062922977N1
Lead Sponsor
Deputy of Research Development Ahvaz Jundishapur University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
120
Inclusion Criteria

Inclusion criteria (consenting NAFLD patients 18-65 years old; evidence of fatty liver in ultrasonography with a score of 2 or more or alanine aminotransferase (ALT) levels up to 60 U/L;) and exclusion criteria (daily alcohol consumption above 20 g in women and 30 g in men; incidence of other acute or chronic liver diseases (hepatitis B, C, etc); cirrhosis; biliary disease; known autoimmune disease; malignancy and/or inherited disorders that affect liver status (an iron storage disease, Wilson disease, etc); pregnancy and lactation; metformin consumption; incidence of hyperlipidemia or hypertension requiring medication; previous supplementation of vitamin E; usage of hepatotoxic drugs over the past 6 months prior to the trial; developing hypersensitivity to cinnamon or occurring any adverse effects; acquiring viral/autoimmune/metabolic hepatic disorders during the study; alcohol intake; withdrawing treatment or being lost to follow up clinical and para-clinical examinations)

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath